

Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028

<https://marketpublishers.com/r/G90B293E1090EN.html>

Date: October 2023

Pages: 470

Price: US\$ 2,800.00 (Single User License)

ID: G90B293E1090EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028

Report Highlights:

Global CD3 Antibodies Market Opportunity: > USD 5 Billion By 2028

Global & Regional Market Trends Analysis

Current Market Trends, Developments & Clinical Trials Assessment

CD3 Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

Clinical Insight On 250 CD3 Antibodies In Clinical Trials

Dosage, Patent, Pricing & Sales Insight on Approved Antibodies

Clinical Insight On 9 Commercially Approved CD3 Antibodies

Clinical Trials, Dosage, Price & Sales Analysis Representations In 100 Graphs & Tables

CD3 is an important component of intracellular signaling and has a critical role in recognition of antigens and the downstream stimulation of T cell response. With the deepening of researchers' knowledge about the immune system, its activation and

suppression, and the subsequent effects in different diseases, CD3 protein has emerged as a promising target that has significant therapeutic potential in various diseases. Over the years, several CD3 antibodies and anti-CD3 antibodies have been developed to assess the therapeutic effects of regulating the activity of CD3, which has led to the market entry of several CD3 antibodies and anti-CD3 antibodies that are performing well in their approved indications. The market for CD3 antibodies, though leans more towards cancer indications, is quite dynamic, with a lot of undiscovered potential, making it a domain to explore.

The first CD3 antibody to receive approval was Muromonab-CD3; this was followed by the approval of Removab (Catumaxomab). However, both these CD3 antibodies were withdrawn from the market for different clinical and commercial reasons, but, nevertheless, positioned themselves as pioneers of the CD3 antibodies market. Newer CD3 antibodies that entered the market after these had various modifications and were based on different technological platforms, which enabled them to avoid the same fate as their predecessors. As a result, there are nine antibodies, which have regulatory approvals from the FDA and EMA.

Among these nine, Blincyto (CD19 ? CD3) was the first to receive approval; it was approved in 2014 and entered the market in 2015, which allowed it to have a head start in the global CD3 antibodies market in terms of commercial performance. Sales of Blincyto have been increasing year because of its increasing uptake, which has been attributed to the drug being one of the most effective immunotherapies for acute lymphoblastic leukemia. Blincyto collected revenue of US\$ 583 million in the year 2022, and in the first half of 2023, the drug has already generated a revenue of US\$ 400 million, making it a dominating player in the global CD3 antibodies market.

It is also important to mention that the remaining eight CD3 antibodies were all approved in the years 2022 and 2023, and are only approved in limited regions, which has been disadvantageous for their sales and their share in the global CD3 antibodies market. All these were approved under the FDA's accelerated approval program and the EMA's conditional marketing approval program, and their continued approvals are awaited. Nevertheless, their developers are seeking approvals in other regions, which will help them generate more revenues in the market, potentially giving competition to Blincyto's stance in the global market.

In terms of the clinical development of CD3 antibodies, different cancer indications are dominating. The approved CD3 antibodies have been approved to treat multiple myeloma, lymphoma, uveal melanoma and leukemia, and the same trend is being seen

for CD3 antibody candidates in development. Moreover, a majority of these candidates are being developed as bispecific antibodies - T cell engagers to be precise - following a similar mechanism of action as Blincyto and other CD3 antibodies approved for use in cancer. Lindis Biotech, BioAtla, AstraZeneca, Regeneron, and Amgen are some pharmaceutical companies that have CD3 bispecific T cell engagers in development.

Based on current commercial trends, the market for CD3 antibodies appears to be thriving, with various factors favorably influencing the market. Among these is the global market value of CD3 antibodies, which has been increasing every quarter as new antibodies are approved and introduced into the market. Another factor is the involvement of important pharmaceutical corporations, which boosts the likelihood of success and financial returns associated with top CD3 antibodies. The invention and use of proprietary platforms, which enabled the development of unique CD3 T cell engagers, allowed developers to construct novel antibodies for rare indications, which came with regulatory benefits such as orphan drug designation. Overall, the global CD3 antibody market has enormous potential, much of which is yet relatively untapped.

Contents

1. RESEARCH METHODOLOGY

2. INTRODUCTION TO CD3 DIRECTED DRUGS

2.1 Overview

2.2 History & Evolution of CD3 Directed Drugs

3. MECHANISM OF ACTION OF CD3 ANTIBODIES

3.1 As Immunosuppressive Therapy

3.2 As Immune Activation Therapy

4. APPLICATION OF CD3 ANTIBODIES BY INDICATION

4.1 Cancer

4.2 Inflammatory & Autoimmune Conditions

5. GLOBAL CD3 ANTIBODIES MARKET & CLINICAL TRIALS OUTLOOK

5.1 Current Market Trends, Developments & Clinical Trials Assessment

5.2 Sales Analysis

5.3 Future Market Opportunities

6. CD3 TARGETING ANTIBODIES MARKET LANDSCAPE BY REGION

6.1 US

6.2 EU

6.3 Canada

6.4 UK

6.5 Japan

7. APPROVED CD3 ANTIBODY DOSAGE, PATENT, PRICE & SALES INSIGHT

7.1 Blincyto – 1st Approved CD3 Antibody

7.2 Kimmtrak – 2nd Approved CD3 Antibody

7.3 Tecvayli – 3rd Approved CD3 Antibody

7.4 Others (6 More CD3 Antibodies)

8. GLOBAL CD3 ANTIBODIES CLINICAL TRIALS OVERVIEW

8.1 By Company

8.2 By Country

8.3 By Indication

8.4 By Phase

8.5 By Patient Segment

9. GLOBAL CD3 ANTIBODIES CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE

9.1 Research

9.2 Preclinical

9.3 Phase-I

9.4 Phase-I/II

9.5 Phase-II

9.6 Phase-III

9.7 Preregistration

10. MARKETED CD3 ANTIBODIES CLINICAL INSIGHT BY COMPANY & INDICATION

11. GLOBAL CD3 INHIBITORS MARKET DYNAMICS

11.1 Drivers & Opportunities

11.2 Challenges & Restraints

12. COMPETITIVE LANDSCAPE

12.1 Abpro Therapeutics

12.2 Adagene

12.3 Amgen

12.4 Astellas Pharma

12.5 Beijing Mabworks Biotech

12.6 BioAtla

12.7 Genentech

- 12.8 Genmab
- 12.9 Harbour BioMed
- 12.10 Harpoon Therapeutics
- 12.11 IGM Biosciences
- 12.12 Immunocore
- 12.13 Integral Molecular
- 12.14 ITabMed
- 12.15 Janssen Research & Development
- 12.16 Janux Therapeutics
- 12.17 KeyMed Biosciences
- 12.18 Light Chain Bioscience
- 12.19 Linton Pharm
- 12.20 MacroGenics
- 12.21 Memorial Sloan-Kettering Cancer Center
- 12.22 Pfizer
- 12.23 Qilu Pharmaceutical
- 12.24 Regeneron Pharmaceuticals
- 12.25 Roche
- 12.26 Sichuan Baili Pharmaceutical
- 12.27 SystImmune
- 12.28 Takeda
- 12.29 Xencor
- 12.30 Zymeworks

Table 7-1: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL

Table 7-2: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL

Table 7-3: Blincyto – Recommended Dose Modifications

Table 7-4: Kimmtrak - Recommended Dosage for Treatment of Unresectable or Metastatic Uveal Melanoma

Table 7-5: Kimmtrak - Dose Modifications for Adverse Reactions

Table 7-6: Tecvayli - Dosing Schedule

Table 7-7: Tecvayli - Recommended Dosage Modifications for Adverse Reactions

Table 7-8: Tzield - Recommended Dosage and Administration

Table 7-9: Lunsumio - Recommended Dose & Schedule for 21-Day Treatment Cycles

Table 7-10: Lunsumio - Recommendations for Management of Cytokine Release Syndrome

Table 7-11: Lunsumio - Recommendations for Management of Neurologic Toxicity (Including ICANS)

Table 7-12: Lunsumio - Recommended Dosage Modification for Adverse Reactions

Table 7-13: Columvi - Dosing Schedule (21-Day Treatment Cycles)

Table 7-14: Columvi - Recommendations for Management of Cytokine Release Syndrome

Table 7-15: Columvi - Recommendations for Management of Neurologic Toxicity (Including ICANS)

Table 7-16: Columvi - Recommended Dosage Modification for Adverse Reactions

Table 7-17: Epkinly - Dosage Schedule

Table 7-18: Epkinly - Recommendations for Management of Cytokine Release Syndrome

Table 7-19: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Table 7-20: Epkinly - Recommended Dosage Modifications for Other Adverse Reactions

Table 7-21: Talvey - Weekly Dosing Schedule

Table 7-22: Talvey – Biweekly Dosing Schedule

Table 7-23: Talvey - Recommendations for Management of CRS

Table 7-24: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Table 7-25: Talvey - Recommendations for Management of Neurologic Toxicity (excluding ICANS)

Table 7-26: Talvey - Recommended Dosage Modifications for Other Adverse Reactions

Table 7-27: Elrexfio - Dosing Schedule

Table 7-28: Elrexfio - Recommendations for Management of CRS

Table 7-29: Elrexfio - Recommended Dosage Modifications for Other Adverse Reactions

Figure 2-1: TCR-CD3 Structure

Figure 2-2: BiTE – Amgen

Figure 2-3: Development & Evolution of CD3 Targeting Antibodies

Figure 3-1: Bispecific T cell Engaging Antibody

Figure 4-1: Elranatamab Phase III MAGNETISMM-5 Study – Initiation & Completion Years

Figure 4-2: Elranatamab Phase III MagnetisMM-7 Study – Initiation & Completion Years

Figure 4-3: Elranatamab Phase III MagnetisMM-6 Study – Initiation & Completion Years

Figure 4-4: Epcoritamab Phase III EPCORE DLBCL-1 Study – Initiation & Completion Years

Figure 4-5: Epcoritamab Phase III EPCORE FL-1 Study – Initiation & Completion Years

Figure 4-6: Epcoritamab Phase III Study – Initiation & Completion Years

Figure 4-7: Talquetamab Phase III MonumentAL-3 Study – Initiation & Completion Years

Figure 4-8: Glofitamab Phase III Study – Initiation & Completion Years

Figure 4-9: LINKER-MM3 Phase III Study – Initiation & Completion Years

Figure 4-10: Tzield - Mechanism of Action

Figure 5-1: Global – CD3 Antibodies Sales (US\$ Million), 2019 - 2023

Figure 5-2: Global – CD3 Antibodies Sales Shares (US\$ Million), H1'2023

Figure 5-3: Global – CD3 Antibodies Sales Shares (%), H1'2023

Figure 5-4: Global – CD3 Antibodies Sales (US\$ Million), 2023 - 2028

Figure 6-1: US vs ROW - CD3 Antibodies Market By Region (US\$ Million), 2022-2023

Figure 6-2: US vs ROW - CD3 Antibodies Market By Region (%), H1'2023

Figure 6-3: US vs ROW - CD3 Antibodies Market By Region (%), 2022

Figure 6-4: US vs ROW - CD3 Antibodies Market By Region (US\$ Million), 2021

Figure 6-5: US vs ROW - CD3 Antibodies Market By Region (%), 2021

Figure 7-1: Blincyto – Approval Years by Region

Figure 7-2: Blincyto – US Patent Acceptance & Expiration Years

Figure 7-3: Blincyto – Europe Patent Expiration Years

Figure 7-4: Blincyto – Treatment Course of MRD-Positive B-cell precursor ALL

Figure 7-5: Blincyto – Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD-Positive B-cell precursor (Days)

Figure 7-6: Blincyto - Cost of Single Cycle & Treatment Course for the Treatment of MRD-positive B-cell Precursor ALL

Figure 7-7: Blincyto – Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL

Figure 7-8: Blincyto – Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)

Figure 7-9: Blincyto - Cost of Single Cycle & Treatment Course for Treatment for Relapsed B-Cell Precursor ALL

Figure 7-10: Global – Blincyto Sales (US\$ Million), 2019-2023

Figure 7-11: US – Blincyto Sales (US\$ Million), 2019-2023

Figure 7-12: ROW – Blincyto Sales (US\$ Million), 2019-2023

Figure 7-13: Global – Quarterly Blincyto Sales (US\$ Million), H1'2023

Figure 7-14: US – Quarterly Blincyto Sales (US\$ Million), H1'2023

Figure 7-15: ROW – Quarterly Blincyto Sales (US\$ Million), H1'2023

Figure 7-16: Global – Quarterly Blincyto Sales (US\$ Million), 2022

Figure 7-17: US – Quarterly Blincyto Sales (US\$ Million), 2022

- Figure 7-18: ROW – Quarterly Blincyto Sales (US\$ Million), 2022
- Figure 7-19: Kimmtrak – Approval Years by Region
- Figure 7-20: Kimmtrak – Cost Per Unit & Per Vial (US\$), October'2023
- Figure 7-21: Global – Kimmtrak Sales (US\$ Million), 2022-H1'2023
- Figure 7-22: Global – Quarterly Kimmtrak Sales (US\$ Million), H1'2023
- Figure 7-23: Kimmtrak – Sales by Region (US\$ Million), H1'2023
- Figure 7-24: US – Quarterly Kimmtrak Sales (US\$ Million), H1'2023
- Figure 7-25: EU – Quarterly Kimmtrak Sales (US\$ Million), H1'2023
- Figure 7-26: ROW – Quarterly Kimmtrak Sales (US\$ Million), H1'2023
- Figure 7-27: Global – Quarterly Kimmtrak Sales (US\$ Million), 2022
- Figure 7-28: Kimmtrak – Sales by Region (US\$ Million), 2022
- Figure 7-29: US – Quarterly Kimmtrak Sales (US\$ Million), 2022
- Figure 7-30: EU – Quarterly Kimmtrak Sales (US\$ Million), 2022
- Figure 7-31: ROW – Quarterly Kimmtrak Sales (US\$ Million), 2022
- Figure 7-32: Tecvayli – Approval Years by Region
- Figure 7-33: Tecvayli – Patent Acceptance & Expiration Years
- Figure 7-34: US – Cost Of 10 mg/ ml Tecvayli Vial (US\$), October'2023
- Figure 7-35: US - Cost Of 90 mg/mL Vial Tecvayli (US\$), October'2023
- Figure 7-36: EU - Cost of 1 mg/ml Vial Tecvayli (EUR v/s US\$), October'2023
- Figure 7-37: EU - Cost of 90 mg/mL Vial Tecvayli (EUR v/s US\$), October'2023
- Figure 7-38: Tzield – Approval Years by Region
- Figure 7-39: Tzield – Cost Of 2 ml Vial (US\$), October'2023
- Figure 7-40: Tzield – Cost Of 20 ml Vial (US\$), October'2023
- Figure 7-41: Tzield – Cost Of 28 ml Vial (US\$), October'2023
- Figure 7-42: Lunsumio – Approval Years by Region
- Figure 7-43: US - Cost Of 1 mg/ml Lunsumio Vial (US\$), October'2023
- Figure 7-44: US - Cost Of 30 mg/30 ml Lunsumio Vial (US\$), October'2023
- Figure 7-45: EU - Cost of 1 mg/ml Lunsumio Vial (EUR v/s US\$), October'2023
- Figure 7-46: EU - Cost Of 30 mg/30 ml Lunsumio Vial (EUR v/s US\$), October'2023
- Figure 7-47: Global – Lunsumio Sales (US\$ Million), 2022-2023
- Figure 7-48: Regional - Lunsumio Quarterly Sales (US\$ Million), H1'2023
- Figure 7-49: Regional - Lunsumio Quarterly Sales (US\$ Million), H1'2023
- Figure 7-50: Lunsumio - Quarterly Sales (US\$ Million), Q3-Q4'2022
- Figure 7-51: Columvi – Approval Years by Region
- Figure 7-52: EU - Cost of 2.5 mg/2.5 mL Columvi Vial (EUR v/s US\$), October'2023
- Figure 7-53: EU - Cost 10 mg/10 mL Columvi Vial (EUR v/s US\$), October'2023
- Figure 7-54: Epkinly – Approval Years by Region
- Figure 7-55: US - Cost of Epkinly (US\$), October'2023
- Figure 7-56: EU - Cost of Epkinly (EUR v/s US\$), October'2023

Figure 7-57: Global – Epkinly Sales (US\$ Million), 2023

Figure 7-58: Global – Quarterly Epkinly Sales (US\$ Million), 2023

Figure 7-59: Talvey – Approval Years by Region

Figure 7-60: Talquetamab – FDA & EMA Designation Years

Figure 7-61: Talvey – Patent Acceptance & Expiration Years

Figure 7-62: Elrexfio – Approval Years by Region

Figure 7-63: Elranatamab – FDA & EMA Designation Years

Figure 8-1: Global – CD3 Antibodies Clinical Pipeline by Company (Numbers), 2023
Till 2028

Figure 8-2: Global – CD3 Antibodies Clinical Pipeline by Country (Numbers), 2023
Till 2028

Figure 8-3: Global – CD3 Antibodies Clinical Pipeline by Indication (Numbers), 2023
Till 2028

Figure 8-4: Global – CD3 Antibodies Clinical Pipeline by Phase (Numbers), 2023 Till

2028

Figure 8-5: Global – CD3 Antibodies Clinical Pipeline by Patient Segment (Numbers),

2023 TILL 2028

I would like to order

Product name: Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028

Product link: <https://marketpublishers.com/r/G90B293E1090EN.html>

Price: US\$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G90B293E1090EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970